eLearning
MODULE NAME: | Buprenorphine-naloxone and long acting injection buprenorphine |
---|---|
MODULE CODE: | L3.2 - 2 |
COURSE NAME: | QUEENSLAND OPIOID TREATMENT PROGRAM |
LEARNING LEVEL: | Level 3 – AOD Treatment Specific Practice |
TARGET AUDIENCE: | Prospective QOTP prescribers (medical and nurse practitioners only) |
MODULE TYPE: | Elective |
MODULE AIM: | This module aims to equip the learner with the knowledge required to safely and effectively prescribe and administer sublingual buprenorphine-naloxone (Suboxone®) and long acting injection buprenorphine (Buvidal® and Sublocade®) for the treatment of opioid dependence. |
LEARNING OUTCOMES: | By the end of this module, learners will be able to:
NB: This is the second module in the QOTP prescriber course which requires successful completion in order to apply for approval as a Level 2 QOTP prescriber in Queensland, whereby you can then apply to prescribe buprenorphine-naloxone and long acting injection buprenorphine formulations to patients. Do not commence this module if you have not already completed the first QOTP module ("Understanding opioid dependence, assessment and treatment") as this module builds upon knowledge and theories contained within this previous course. Further completion of a third module "Buprenorphine-mono and methadone prescriber training" followed by a clinical placement shadowing an existing Level 1 prescriber - is required in order to become a 'Level 1 Full QOTP Prescriber', whereby you can prescribe all opioid dependence treatment medications available in Queensland. |
LENGTH: | 1 hour |
CPD: | This module is accredited for:
Please refer to your Statement of Completion for full details. NB: Insight uploads CPD hours quarterly to ACRRM and RACGP. |
REFERENCES: | Click here to download the reference list for this module. |
LAST UPDATED: | August 2023 |